FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3189051104> ?p ?o ?g. }

• W3189051104 endingPage "387" @default.
• W3189051104 startingPage "372" @default.
• W3189051104 abstract "ONC201 is a first-in-class imipridone compound that is in clinical trials for the treatment of high-grade gliomas and other advanced cancers. Recent studies identified that ONC201 antagonizes D2-like dopamine receptors at therapeutically relevant concentrations. In the current study, characterization of ONC201 using radioligand binding and multiple functional assays revealed that it was a full antagonist of the D2 and D3 receptors (D2R and D3R) with low micromolar potencies, similar to its potency for antiproliferative effects. Curve-shift experiments using D2R-mediated β-arrestin recruitment and cAMP assays revealed that ONC201 exhibited a mixed form of antagonism. An operational model of allostery was used to analyze these data, which suggested that the predominant modulatory effect of ONC201 was on dopamine efficacy with little to no effect on dopamine affinity. To investigate how ONC201 binds to the D2R, we employed scanning mutagenesis coupled with a D2R-mediated calcium efflux assay. Eight residues were identified as being important for ONC201's functional antagonism of the D2R. Mutation of these residues followed by assessing ONC201 antagonism in multiple signaling assays highlighted specific residues involved in ONC201 binding. Together with computational modeling and simulation studies, our results suggest that ONC201 interacts with the D2R in a bitopic manner where the imipridone core of the molecule protrudes into the orthosteric binding site, but does not compete with dopamine, whereas a secondary phenyl ring engages an allosteric binding pocket that may be associated with negative modulation of receptor activity. SIGNIFICANCE STATEMENT: ONC201 is a novel antagonist of the D2 dopamine receptor with demonstrated efficacy in the treatment of various cancers, especially high-grade glioma. This study demonstrates that ONC201 antagonizes the D2 receptor with novel bitopic and negative allosteric mechanisms of action, which may explain its high selectivity and some of its clinical anticancer properties that are distinct from other D2 receptor antagonists widely used for the treatment of schizophrenia and other neuropsychiatric disorders." @default.
• W3189051104 created "2021-08-16" @default.
• W3189051104 creator A5002533704 @default.
• W3189051104 creator A5008547275 @default.
• W3189051104 creator A5012110693 @default.
• W3189051104 creator A5015562626 @default.
• W3189051104 creator A5022343281 @default.
• W3189051104 creator A5025947629 @default.
• W3189051104 creator A5034202004 @default.
• W3189051104 creator A5056446196 @default.
• W3189051104 creator A5056800304 @default.
• W3189051104 creator A5076880355 @default.
• W3189051104 creator A5079844419 @default.
• W3189051104 creator A5085900594 @default.
• W3189051104 creator A5091303710 @default.
• W3189051104 date "2021-08-05" @default.
• W3189051104 modified "2023-10-10" @default.
• W3189051104 title "Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D₂ Dopamine Receptor" @default.
• W3189051104 cites W1487834525 @default.
• W3189051104 cites W1833104430 @default.
• W3189051104 cites W1901896114 @default.
• W3189051104 cites W1965926793 @default.
• W3189051104 cites W1976266427 @default.
• W3189051104 cites W1981952236 @default.
• W3189051104 cites W1988821183 @default.
• W3189051104 cites W2016670931 @default.
• W3189051104 cites W2019226300 @default.
• W3189051104 cites W2044217732 @default.
• W3189051104 cites W2055915685 @default.
• W3189051104 cites W2065283382 @default.
• W3189051104 cites W2069849124 @default.
• W3189051104 cites W2074631079 @default.
• W3189051104 cites W2087688448 @default.
• W3189051104 cites W2089626755 @default.
• W3189051104 cites W2097744565 @default.
• W3189051104 cites W2121232930 @default.
• W3189051104 cites W2126132542 @default.
• W3189051104 cites W2162606162 @default.
• W3189051104 cites W2208581158 @default.
• W3189051104 cites W2224214468 @default.
• W3189051104 cites W2260201596 @default.
• W3189051104 cites W2571225631 @default.
• W3189051104 cites W2600944061 @default.
• W3189051104 cites W2735454576 @default.
• W3189051104 cites W2770901406 @default.
• W3189051104 cites W2782946720 @default.
• W3189051104 cites W2783787114 @default.
• W3189051104 cites W2785023044 @default.
• W3189051104 cites W2791804685 @default.
• W3189051104 cites W2806328383 @default.
• W3189051104 cites W2886576780 @default.
• W3189051104 cites W2890053418 @default.
• W3189051104 cites W2902049135 @default.
• W3189051104 cites W2904387354 @default.
• W3189051104 cites W2912818999 @default.
• W3189051104 cites W2937030578 @default.
• W3189051104 cites W2941632024 @default.
• W3189051104 cites W2943151208 @default.
• W3189051104 cites W2950749236 @default.
• W3189051104 cites W2963864951 @default.
• W3189051104 cites W2989611985 @default.
• W3189051104 cites W3002566379 @default.
• W3189051104 cites W3005368593 @default.
• W3189051104 cites W3017499952 @default.
• W3189051104 cites W3021221826 @default.
• W3189051104 cites W3034410769 @default.
• W3189051104 cites W3088361836 @default.
• W3189051104 cites W3093671722 @default.
• W3189051104 cites W3110629517 @default.
• W3189051104 cites W3115770555 @default.
• W3189051104 cites W3133930459 @default.
• W3189051104 cites W3135669159 @default.
• W3189051104 cites W2995833893 @default.
• W3189051104 doi "https://doi.org/10.1124/molpharm.121.000336" @default.
• W3189051104 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8626643" @default.
• W3189051104 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34353882" @default.
• W3189051104 hasPublicationYear "2021" @default.
• W3189051104 type Work @default.
• W3189051104 sameAs 3189051104 @default.
• W3189051104 citedByCount "10" @default.
• W3189051104 countsByYear W31890511042021 @default.
• W3189051104 countsByYear W31890511042022 @default.
• W3189051104 countsByYear W31890511042023 @default.
• W3189051104 crossrefType "journal-article" @default.
• W3189051104 hasAuthorship W3189051104A5002533704 @default.
• W3189051104 hasAuthorship W3189051104A5008547275 @default.
• W3189051104 hasAuthorship W3189051104A5012110693 @default.
• W3189051104 hasAuthorship W3189051104A5015562626 @default.
• W3189051104 hasAuthorship W3189051104A5022343281 @default.
• W3189051104 hasAuthorship W3189051104A5025947629 @default.
• W3189051104 hasAuthorship W3189051104A5034202004 @default.
• W3189051104 hasAuthorship W3189051104A5056446196 @default.
• W3189051104 hasAuthorship W3189051104A5056800304 @default.
• W3189051104 hasAuthorship W3189051104A5076880355 @default.
• W3189051104 hasAuthorship W3189051104A5079844419 @default.
• W3189051104 hasAuthorship W3189051104A5085900594 @default.
• W3189051104 hasAuthorship W3189051104A5091303710 @default.
• W3189051104 hasBestOaLocation W31890511041 @default.

• next